Food effect on the oral bioavailability of manidipine: Single dose, randomized, crossover study in healthy male subjects

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 2, 1998, Pages 197-202

  Rosillon, D ^a   Stockis, A ^a   Poli, G ^c   Acerbi, D ^c   Lins, R ^b   Jeanbaptiste, B ^a  

^a Bio Pharma SA   (Belgium)

^b Stuivenberg General Hospital   (Belgium)

^c CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

Bioavailability; Dihydropyridinic calcium antagonist; Food interaction; Healthy subjects; Manidipine; Pharmacokinetics

Indexed keywords

CALCIUM ANTAGONIST; MANIDIPINE;

ADULT; AREA UNDER THE CURVE; BILE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COULOMETRY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FOOD INTAKE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIPOPHILICITY; MALE; MEAN RESIDENCE TIME; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SOLUBILIZATION;

EID: 0031718475     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03189339     Document Type: Conference Paper

References (28)

1. Iwata A., Tochikubo O., Kawano Y., et al. (1992): A study of the effects of manidipine on the diurnal variation of arterial pressure and hemodynamics in patients with essential hypertension. Blood Pressure, 1 (Suppl. 3): 87-93.
2. Mizuno K., Haga H., Takahaski M., et al. (1992): Clinical evaluation of the efficacy and safety of manidipine in hypertensive patients with renal disorders. Blood Pressure, 1 (Suppl. 3): 119-123.
3. Hirakata H., Iino K., Ishida I., et al. (1992): Effects of a new calcium antagonist, manidipine, on the renal hemodynamics and the vasoactive humoral factors in patients with diabetes mellitus. Blood Pressure, 1 (Suppl. 3), 124-129.
4. Morimoto S., Matsumura Y. (1991): Manidipine hydrochloride [CV-4093(2HCl)]. Cardiovas. Drugs Rev., 9: 207-222
5. Welling P.G. (1993): Necessity of food studies: implication of food effects. In: Midha K.K., Blume H.H. (eds). Bio-International. Bioavailability, bioequivalence and pharmacokinetics, 92. Medpharm, Stuttgart, pp 211-221.
6. Tateno M. (1989): Pharmacokinetic study of CV-4093 (2HCl) at single dose on healthy subjects. J. Clin. Ther. Med., 5 (9): 1765-1790.
7. Gibaldi M., Perrier D. (1982): Pharmacokinetics. 2nd edition. Marcel Dekker, New York.
8. Fleiss J.L. (1986): The design and analysis of clinical experiments. Wiley Interscience, New York.
9. Steinijans V.W., Hauschke D. (1990): Update on the statistical analysis of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol. 28: 105-110.
10. Westlake W.J. (1988): Bioavailability and bioequivalence of pharmaceutical formulations. In : Peace KB (ed). Biopharmaceutical statistics for drug development. Marcel Dekker, New York, pp 329-352.
11. Steinijans V.W., Sauter R. (1993): Food studies: acceptance criteria and statistics. In: Midha K.K., Blume H.H. (eds). Bio-International. Bioavailability, bioequivalence and pharmacokinetics, 92. Medpharm, Stuttgart, pp: 335-250.
12. Chow S.C., Liu J.P. (1992): Design and analysis of bioavailability and bioequivalence studies. Marcel Dekker, New York.
13. Hauschke D., Steinijans V.W., Diletti E. (1990): A distribution-free procedure for the statistical analysis of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol., 28: 72-78.
14. Metzler C.M. (1988): Statistical methods for deciding bioequivalence of formulations. In: Yacobi A., Halperin-Walega E. (Eds). Oral sustained release formulations: Design and evaluation. Pergamon Press, New York, pp: 217-238.
15. Gibaldi M., (1991): Biopharmaceutics and Clinical Pharmacokinetics 4th Edition. Lea & Febiger.
16. Shimizu T., et al. (1993) Influence of food on the blood level and anti-hypertensive efficacy of calcium channel antagonist. Jpn J. Hosp. Pharm., 19 (6): 534-541.
17. Dunselman P.H.J.M., Edgar B. (1991): Felodipine clinical pharmacokinetics. Clin. Pharmacokinet., 21 (6): 418-430.
18. Ahnoff M., Persson B.A. (1990) Chromatography of calcium channel blockers. J. Chromatogr., 531: 181-213.
19. Challenor V.F., Waller D.G., Gruchy B.S., Renwick A.G., George C.F. (1987): Food and nifedipine pharmacokinetics. Br. J. Clin. Pharmacol., 23: 248-249.
20. Rietberg D.P., Love S.J., Zinny M. (1985): Effect of food on nifedipine pharmacokinetics. Clin. Pharmacol. Ther., 37: 223.
21. Rietberg D.P., Love S.J., Quercia G.T., Zinny M.A. (1987): Effect of food on nifedipine pharmacokinetics. Clin. Pharmacol. Ther., 42: 72-75.
22. Rimoy G.H., Idle J.R., Bhashar N.K., Rubin P.C. (1989): The influence of food on the pharmacokinetics of 'biphasic' nifedipine at steady state in normal subjects. Br. J. Clin. Pharmacol., 28: 612-615.
23. Ueno K., Kawashima S., Matsumoto K., Miyai K., Yamauchi K., Yamazaki K. (1991): Effect of light breakfast on the bioavailability of sustained release nifedipine. DICP- Ann. Pharmacotherapy, 25: 317-319.
24. Faulkner J.K., Hayden M.L., Chasseaud L.F., et al. (1989): Absorption of amlodipine unaffected by food: solid dose equivalent to solution dose. Arzneimittelforschung, 39: 799-801.
25. Abernethy D.R. (1989): The pharmacokinetic profile of amlodipine. Am. Heart. J., 118: 1100-1103.
26. Abernethy D.R. (1991): Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist. J. Cardiovasc. Pharmacol., 17: S4-S7.
27. Schran H.F., Jaffe J.M., Gonasum L.M. (1988): Clinical pharmacokinetics of isradipine. Am. J. Med., 84: 80-89.
28. Terakawa M., Tokuma Y., Shishido A., et al.(1987): Effect of two different meals on bioavailability of nilvadipine in healthy volunteers. J. Clin. Pharmacol., 27: 293-296.